EpiVax and CUBRC win $1M FDA contract to establish best practices for assessing generic peptide drugs

EPIVAX AND CUBRC have been awarded a two-year, $1 million federal contract from the U.S. Food and Drug Administration to establish best practices and procedures for assessing generic peptides and related impurities for immunogenic potential. EpiVax CEO and Chief Science Officer Dr. Anne S. De Groot said generic peptides drugs are a quickly growing market. / PBN FILE PHOTO/MICHAEL SALERNO
EPIVAX AND CUBRC have been awarded a two-year, $1 million federal contract from the U.S. Food and Drug Administration to establish best practices and procedures for assessing generic peptides and related impurities for immunogenic potential. EpiVax CEO and Chief Science Officer Dr. Anne S. De Groot said generic peptides drugs are a quickly growing market. / PBN FILE PHOTO/MICHAEL SALERNO
PROVIDENCE – EpiVax Inc. and CUBRC Inc. have been awarded a two-year, $1 million federal contract from the U.S. Food and Drug Administration to establish best practices and procedures for assessing generic peptides and related impurities for immunogenic potential, EpiVax announced Tuesday. EpiVax CEO and Chief Science Officer Dr. Anne S. De Groot told PBN…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -